Genprex Inc GNPX
News
-
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
-
Genprex to Participate at BIO International Convention 2026
-
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
-
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
-
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
-
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
-
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
-
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
Trading Information
- Previous Close Price
- $8.00
- Day Range
- $7.01–7.94
- 52-Week Range
- $7.01–1,210.00
- Bid/Ask
- $7.11 / $7.99
- Shares Outstanding
- 504,936.00
- Market Cap
- $3.87M
- Volume/Avg
- 376,681 / 34,519
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.genprex.com
Valuation
|
Metric
|
GNPX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.19 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GNPX
Financial Strength
|
Metric
|
GNPX
|
|---|---|
Quick Ratio | 5.38 |
Current Ratio | 5.61 |
Interest Coverage | — |
Quick Ratio
GNPX
Profitability
|
Metric
|
GNPX
|
|---|---|
Return on Assets (Normalized) | −188.35% |
Return on Equity (Normalized) | −267.22% |
Return on Invested Capital (Normalized) | −264.94% |
Return on Assets
GNPX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!?%Kq? | LOCK|ssMV? | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|hqS?PP! | LOCK|<!@g | $71B | |||
| argenx SE ADR
ARGX
| LOCK|VY?n>nk | LOCK|ks | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|JYV$qDF | LOCK|P?$ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|K>C!jL | LOCK|nwFh | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>Rrc%jw! | LOCK|^@!@> | $26B | |||
| Moderna Inc
MRNA
| LOCK|XD%!Lp! | LOCK|^X | $25B | |||
| Incyte Corp
INCY
| LOCK|W^JgRf& | LOCK|Y!d | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!<#lj@! | LOCK|&T? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$BV%W&# | LOCK|C@H | $16B |
United States